Fluticasone Powder

Description

Fluticasone Powder

Background
Fluticasone is a corticosteroid medication demonstrating potent anti-inflammatory activity that decreases inflammation through an unknown mechanism of action. However, corticosteroids are thought to act by the induction of phospholipase A₂ which leads to the inhibition of a common precursor for potent inflammatory mediators. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption (1).

Fluticasone is commercially available in the following dosage forms: topical cream, topical lotion, topical ointment, nasal spray and various aerosols and powders for inhalation.

Regulatory Status
FDA approved topical indication: Fluticasone is a medium potency corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (1).

The safety and efficacy of fluticasone in pediatric patients below 3 months of age have not been established (1).

Related policies
Mometasone powder
Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Fluticasone powder may be considered medically necessary in a topical formulation for patients 3 months of age or older for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Fluticasone powder may be considered investigational in a topical formulation for patients under the age of 3 months and for all other indications.

Prior-Approval Requirements

Age  3 months or older

Diagnoses

Patient must have the following:

1. Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (including but not limited to hives, rash, eczema, dermatitis)

AND ALL of the following:

1. The patient must have tried and failed and/or have an intolerance to an existing commercially available topical product
2. All of the active ingredients in the formulation are prescription (RX) only products and are FDA approved for inflammatory and pruritic dermatoses
3. The concentration of the final product will not exceed the FDA approved limits of 0.05%
4. It is not being used for cosmetic purposes (including but not limited to anti-aging, anti-wrinkle, hair growth/removal, scar prevention, scar diminishing, skin lightening/tanning)

Prior – Approval Renewal Requirements

Same as above
Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Duration 6 months

Prior – Approval Renewal Limits

Duration 6 months

Rationale

Summary

Topical steroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. Fluticasone is FDA-approved for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. The safety and efficacy of fluticasone in pediatric patients below 3 months of age have not been established. Fluticasone is commercially available in the following dosage forms: topical cream, topical lotion, topical ointment, nasal spray and various aerosol and powders for inhalation (1).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of fluticasone powder while maintaining optimal therapeutic outcomes.

References

### 5.99.11

<table>
<thead>
<tr>
<th>Section:</th>
<th>Prescription Drugs</th>
<th>Effective Date:</th>
<th>July 1, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subsection:</td>
<td>Miscellaneous Products</td>
<td>Original Policy Date:</td>
<td>May 12, 2014</td>
</tr>
<tr>
<td>Subject:</td>
<td>Fluticasone Powder</td>
<td>Page:</td>
<td>4 of 4</td>
</tr>
</tbody>
</table>

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 22, 2017 and is effective on July 1, 2017.